Product Datasheet

TRAF-1 Antibody (TRAF1/3298) [Alexa Fluor® 488] NBP2-79925AF488

Unit Size: 0.1 ml

Store at 4C in the dark.

www.novusbio.com

G

technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP2-79925AF488

Updated 10/26/2023 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBP2-79925AF488



NBP2-79925AF488

TRAF-1 Antibody (TRAF1/3298) [Alexa Fluor® 488]

Product Information Unit Size 0.1 ml Concentration Please see the vial label for concentration. If unlisted please contact technical services. Storage Store at 40 in the dark. Clonality Monoclonal Clone TRAF1/3298 Preservative 0.05% Sodium Azide Isotype IgG2b Kappa Conjugate Alexa Fluor 488 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description This S Gene ID 7185 Gene Bymbol TRAF1 Species Human Marker Lymphomatoid Papulosis Marker Specificity/Sensitivity This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive TOLS. Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous T-oel lymphomas (CTCLs). Besides borderline cases this doing in their propriosi. In particular, common facture of both cases is histologically, the presence of atypical lymphod CJ30-positive To basts and genetically a chonal T-cell-receptor rearrangement. However, buch cases differ considerably in their proprios. In particular, common facture of both cases is histologically in their proprios. In particular, common facture of both cases is histologically in their propricore rearrangement. However, buch cases differ	, , , , , , , , , , , , , , , , , , , ,	•
Concentration Please see the vial label for concentration. If unlisted please contact technical services. Storage Store at 4C in the dark. Clonality Monoclonal Clone TRAF1/3298 Preservative 0.05% Sodium Azide Isotype IgG2b Kappa Conjugate Alexa Fluor 488 Purity Protein A or G purified Buffer 50m Sodium Borate Product Description Host Host Mouse Gene ID 7185 Gene Symbol TRAF1 Species Human Marker Lymphomatoid Papulosis Marker Specificity/Sensitivity This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1), CD30-positive upmhoproliferations of the sis histologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is in bistologically, intrunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is inistologically in their connect or atypical Umphora (CALCL). Although the two entilies considerably in their connect or atypical Umphora (CALCL). Although the devect, LyP patients do not benefit from an aggressive radio- and/or chemotherapueutic approach, in contrast to patients with ALCL. Besides. LyP	Product Information	
services. Storage Store at 4C in the dark. Clonality Monoclonal Clone TRAF1/3298 Preservative 0.05% Sodium Azide Isotype IgG2b Kappa Conjugate Alexa Fluor 488 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description Host Host Mouse Gene ID 7185 Gene Symbol TRAF1 Species Human Marker Lymphomatoid Papulosis Marker Specificity/Sensitivity This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphomais (CTCLs). Besides borderline cases this group includes lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they adient course Lesions of LyP erges spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do no thenefit from an aggressive radio- and cALCL differ strongly in their considerably in their considerably in their progonosi. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive To blasts and genetically, in their orman aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL Besides_LPP and cALCL differ strongly in theergession on TRAF1 (tumor necrois factor receptor (TNFR	Unit Size	0.1 ml
Clonality Monoclonal Clone TRAF1/3298 Preservative 0.05% Sodium Azide Isotype IgG2b Kappa Conjugate Alexa Fluor 488 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description House Gene ID 7185 Gene ID 7185 Gene Symbol TRAF1 Species Human Marker Lymphomatoid Papulosis Marker Specificity/Sensitivity This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR4) TCNFA-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomoma feature of both cases is histologically in their considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoma (CALCL). Although the two entities overlap clinically histopathologically, in particular, common feature of both cases is histologically in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and Spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated by is how a strong TRAF	Concentration	
CloneTRAF1/3298Preservative0.05% Sodium AzideIsotypeIgG2b KappaConjugateAlexa Fluor 488PurityProtein A or G purifiedBuffer50mM Sodium BorateProduct DescriptionHostMouseGene ID7185Gene SymbolTRAF1SpeciesHumanMarkerLymphomatoid Papulosis MarkerSpecificity/SensitivityThis monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (CALCL). Although the two entities genetically, a clonal T-cell-receptor rearrangement. Horever, bot cases is histologically in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress ad spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL besides. Jury Pade CALCL iffer storogly in the expression of TNRAF1 expression, tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of most LyP cases (ca. 84%) sh	Storage	Store at 4C in the dark.
Preservative 0.05% Sodium Azide Isotype IgG2b Kappa Conjugate Alexa Fluor 488 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description House Gene ID 7185 Gene Symbol TRAF1 Species Human Marker Lymphomatoid Papulosis Marker Specificity/Sensitivity This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (CALCL). Although the two entities overlap clinically, histopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their of parties in a dry progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of most LyP cases (ca. 84%) show a strong TAF1 expression, tumor cells of most LyP cases (ca. 84%) show a strong TAF1 expression in only a few cases (ca. 7%). An	Clonality	Monoclonal
Isotype IgG2b Kappa Conjugate Alexa Fluor 488 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description	Clone	TRAF1/3298
Conjugate Alexa Fluor 488 Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description Host Host Mouse Gene ID 7185 Gene Symbol TRAF1 Species Human Marker Lymphomatoid Papulosis Marker Specificity/Sensitivity This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically and penetically, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Beides, LyP and cALCL differ strongly in the expression of TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differention of LyP and cALCL in patients with cutaneous CD30-positive lymphorpilferations.	Preservative	0.05% Sodium Azide
Purity Protein A or G purified Buffer 50mM Sodium Borate Product Description Mouse Gene ID 7185 Gene Symbol TRAF1 Species Human Marker Lymphomatoid Papulosis Marker Specificity/Sensitivity This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a conal T-cell-receptor rearrangement. However, but cases differ considerably in their prognosis. In particular, common feature of both cases is histologically and genetically and genetically and genetically in their prognosis and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR i signaling: Whereas tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphorpilferations.	Isotype	IgG2b Kappa
Buffer 50mM Sodium Borate Product Description Mouse Gene ID 7185 Gene Symbol TRAF1 Species Human Marker Lymphomatoid Papulosis Marker Specificity/Sensitivity This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TMFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of rALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphorpoliferations.	Conjugate	Alexa Fluor 488
Product Description Host Mouse Gene ID 7185 Gene Symbol TRAF1 Species Human Marker Lymphomatoid Papulosis Marker Specificity/Sensitivity This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of cALCL reveal TRAF1 expression of up a devecases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations. Immunogen Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact	Purity	Protein A or G purified
Host Mouse Gene ID 7185 Gene Symbol TRAF1 Species Human Marker Lymphomatoid Papulosis Marker Specificity/Sensitivity This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALC). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.	Buffer	50mM Sodium Borate
Gene ID 7185 Gene Symbol TRAF1 Species Human Marker Lymphomatoid Papulosis Marker Specificity/Sensitivity This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)- associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations. Immunogen Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact	Product Description	
Gene Symbol TRAF1 Species Human Marker Lymphomatoid Papulosis Marker Specificity/Sensitivity This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations. Immunogen Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact	Host	Mouse
SpeciesHumanMarkerLymphomatoid Papulosis MarkerSpecificity/SensitivityThis monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (CALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of CALCL presist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with CALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)- associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoroliferations.ImmunogenRecombinant fragment of human TRAF-1 protein (around aa 73-219) (exact	Gene ID	7185
MarkerLymphomatoid Papulosis MarkerSpecificity/SensitivityThis monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)- associated factor 1), a component of TNFR signaling: Whereas tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.ImmunogenRecombinant fragment of human TRAF-1 protein (around aa 73-219) (exact	Gene Symbol	TRAF1
Specificity/SensitivityThis monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)- associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.ImmunogenRecombinant fragment of human TRAF-1 protein (around aa 73-219) (exact	Species	Human
TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)- associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.ImmunogenRecombinant fragment of human TRAF-1 protein (around aa 73-219) (exact	Marker	Lymphomatoid Papulosis Marker
	Specificity/Sensitivity	TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of CALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with
	Immunogen	



	Alexa Fluor (R) products are provided under an intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: (i) in manufacturing; (ii) to provide a service, information, or data in return for payment; (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Product Application Details	
Applications	Immunohistochemistry, Immunohistochemistry-Paraffin, Protein Array
Recommended Dilutions	Immunohistochemistry, Immunohistochemistry-Paraffin, Protein Array
Application Notes	Optimal dilution of this antibody should be experimentally determined.

Notes





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112 USA Phone: 303.730.1950 Toll Free: 1.888.506.6887 Fax: 303.730.1966 nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6 Canada Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402 canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449 Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com Technical Support: nb-technical@biotechne.com Orders: nb-customerservice@bio-techne.com General: novus@novusbio.com

Products Related to NBP2-79925AF488

NBP1-43317AF488Mouse IgG2b Kappa Light Chain Isotype Control (MG2b) [Alexa Fluor®
488]NB100-56171PEPTRAF-1 Antibody Blocking Peptide210-TA-005TNF-alpha [Unconjugated]NB100-56170PEPTRAF-1 Antibody Blocking Peptide

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-79925AF488

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

www.novusbio.com

